Chronic hepatitis C is the most common infectious disease among injection drug users (IDUs). Because of the allegedly poor compliance of IDUs with treatment requirements and conditions, hepatologists recommend treatment only if former IDUs have spent 6 to 12 months drug free. The aim of this prospective study was to investigate whether opiate-dependent IDUs with chronic hepatitis C virus (HCV) infection can be treated successfully with interferon. Eligibility for the study meant IDUs had to be HCV-RNA positive by polymerase chain reaction. Subsequently 50 inpatients were enrolled during detoxification treatment. HCV treatment was started with interferon alfa-2a (through 1998) or a combined regimen consisting of interferon alfa-2a and ribavirin (begun in 1998). All patients were treated and supervised by specialized physicians in both hepatology and addiction medicine. The end point for this study was defined as a loss of detectable serum HCV RNA at week 24 after treatment. The rate of sustained virologic response was 36%. Sustained response rates were not significantly different for patients who relapsed and returned to treatment (53%), relapsed and did not return to treatment (24%), or did not relapse (40%; P > .05). During the 24 weeks after treatment, we were unable to detect any reinfection, even among patients who injected heroin during this period. This surprising result should be examined in further studies. In conclusion, HCV-infected drug addicts with chronic HCV infection can be treated successfully with interferon alfa-2a and ribavirin if they are closely supervised by physicians specialized in both hepatology and addiction medicine. (HEPATOLOGY 2001;34:188-193.) Intravenous drug addiction is a high-risk factor for acquiring chronic hepatitis C virus (HCV) infection. 1-6 Serologic testing for antibodies to HCV has shown that between 36% and 95% of intravenous drug users (IDUs) have been exposed to HCV. 7-13 Injection of illicit drugs currently accounts for most HCV transmission in the United States.
Intravenous drug addiction is a high-risk factor for acquiring chronic hepatitis C virus (HCV) infection. [1] [2] [3] [4] [5] [6] Serologic testing for antibodies to HCV has shown that between 36% and 95% of intravenous drug users (IDUs) have been exposed to HCV. [7] [8] [9] [10] [11] [12] [13] Injection of illicit drugs currently accounts for most HCV transmission in the United States. 1, 4, 14 Between 75% and 85% of persons with acute HCV infection develop chronic HCV infection with or without alanine aminotransferase abnormalities, 15, 16 and between 8% and 25% of these patients develop cirrhosis within 10 to 20 years 17 with the risk of liver failure, hepatocellular carcinoma, and liver-related deaths. 18, 19 Until 1998, administration of interferon alfa for 48 weeks was the only effective treatment of hepatitis C. [20] [21] [22] [23] In the autumn of 1998, 2 studies were published showing that a combination of interferon alfa-2b and ribavirin improves the chance of sustained viral elimination in previously untreated patients with genotype 1 up to 40%. 24, 25 This has become the standard treatment for naive nonaddicted patients with genotype 1. For patients who are currently injecting illegal drugs or drinking excessive amounts of alcohol, HCV treatment with interferon alfa and ribavirin is still not recommended 27, 28 on the grounds that the compliance of the IDUs is poor and the risk of reinfection high if they continue to inject drugs. However, to our knowledge the compliance of IDUs with hepatitis C treatment has not been investigated. For this reason we conducted the following prospective trial. We believe that treatment and care by a specialist in addiction medicine improves the patients' compliance considerably. Effective treatment of HCV in IDUs could greatly reduce the general population's risk of becoming infected.
In the present study, the hypothesis that IDUs with chronic HCV infection can be treated successfully with interferon alfa-2a or a combination of interferon alfa-2a and ribavirin was investigated.
PATIENTS AND METHODS
Patients. Since November 1997, all patients admitted to our detoxification unit have been tested for anti-HCV using a second-generation enzyme immunoassay and for HCV RNA by polymerase chain reaction. Liver biopsies were not taken. Virus load was determined by Cobas Amplicor HCV Monitor test (Roche Diagnostics, Branchburg, NJ). Only patients who tested positive for HCV RNA, had volunteered to participate in a 12-or 24-month study, and had met the current ICD-10 diagnosis of opioid or opiate dependence (ICD-10: F11.2) with an additional dependence on alcohol (ICD-10: F10.2), benzodiazepine (ICD-10: F13.2), or cocaine (ICD-10: F14.2) were included. Exclusion criteria were pregnancy, unsafe contraception, severe depression, and seropositivity for human immunodeficiency virus. In all, 50 patients were enrolled.
Funding of Drug Treatment and Other Medical Care in Germany. In principle, detoxification treatment and therapeutic substitution with methadone or HCV treatment with interferon is usually paid for by public health insurance in Germany. For patients lacking health insurance coverage, the social services department (i.e., the state) pays the expenses if the physician deems it necessary that a patient receive treatment. Patients are expected to pay between 3 Euro and 15 Euro when they convert a prescription. Patients without the means to pay even these costs can apply to have them paid by the state. In Germany, 70% of all IDUs are covered by health insurance, and 30% have their medical expenses paid for them by the social services department.
Treatment Setting: The Detoxification Unit. Our detoxification unit is a physically separate ward of a large medical department within a general hospital. It is located in what was formerly the director's mansion (thus colloquially called the "Villa") within the hospital compound and has 15 beds for opiate addicts. The treatment strategies known in Germany as "qualified detoxification" consist of medication-supported detoxification (preferentially methadone), diagnosis and treatment of other diseases (hepatitis B and C, acquired immunodeficiency syndrome, pneumonia, etc.), psychotherapy and social therapy, and a transition to an abstinence phase after detoxification. The Villa is conceptualized as "low-threshold" treatment. Admission is without preparation or preconditions. Patients can contact the unit via hotline telephone. They may come of their own accord; previous contact with a counselor or a physician is not necessary. Admissions to the unit are Mondays through Wednesdays. The order of admission is according to perceived severity of drugassociated problems and a waiting list. The unit is supervised by 2 physicians, 1 psychologist, 6 social workers, and 6 nurses. No outside visitors are allowed during the hospital stay. In the first 24 hours (regardless of the patient's preferred opiate, e.g., methadone, dihydrocodeine, or heroin), a methadone dose was prescribed in accordance with the clinical evaluation. Withdrawal symptoms were kept to a minimum. The methadone dosage was determined by the physician according to the patient's self-reported opiate intake, the method in which it was taken (sniffing, intravenous injection), and the results of urine screening tests. Estimation of the heroin dose is based on the current average grade of purity of heroin found by the police. Overall, the analyses showed an average purity of heroin of 33%. If patients were diagnosed as having additional substance dependencies, such as benzodiazepines or alcohol, appropriate additional treatment with diazepam, carbamazepine, or clomethiazol was initiated. The medication-supported detoxification enabled most patients to participate in the sociopsychotherapy part of the program starting on the day of admission. This therapy included 2 group sessions and 1 individual session each day. In addition, a "group information session" was held once a week by one of the doctors. The main topics here were how to prevent an overdose, how to administer first aid, and how to protect oneself from contagious diseases. 11, 26 Treatment Schedule. All patients were examined and treated during the study time by the same 3 physicians. All 3 are specialists in both hepatology and addiction medicine. The first HCV treatment was initiated during detoxification treatment. Patients were instructed about what they can do to minimize their risk of becoming infected or of transmitting infectious agents to others, e.g., by not sharing syringes or needles or any injection equipment, and by avoiding blood contact. Prior to treatment, the patients were asked to consider whether the interferon treatment and the use of needles might lead to drug craving and a relapse. All patients were quite certain that this would not become a problem. The length of the inpatient sojourn was determined in accordance with the severity of the withdrawal process. Two weeks before a patient was to be discharged, HCV treatment was initiated (6 injections). Patients were taught the injection technique. Of the 6 injections of interferon alfa-2a, two were performed by the patients themselves under a doctor's supervision. Interferon alfa-2a and ribavirin were prescribed by us or by patients' physicians. An interferon alfa-2a prescription covers 30 injections or 10 weeks. When patients were discharged from the inpatient detoxification unit, they were either sent home, where they continued visiting the hospital weekly on an outpatient basis, or were transferred to a special clinic with an abstinence program. Patients who relapsed were offered replacement therapy with methadone or dihydrocodeine. They were allowed to continue their HCV treatment through any of these contingencies, even if they injected heroin again. After leaving the detoxification unit, patients were assessed weekly regarding their condition and progress by 1 of the 3 specialists either in an outpatient or inpatient setting (abstinence program). Criteria were whether they were (1) treated in an inpatient abstinence program, (2) living at home, (3) receiving methadone or dihydrocodeine in a maintenance program after having had a drug relapse, or (4) injecting heroin again. In addition, they were questioned as to how many interferon injections they had missed. It was also noted whether they appeared for the prearranged blood test every 12 weeks. Once each month they had the opportunity to participate in a session of dynamic-oriented psychotherapy.
Until October 1998, all patients were given interferon alfa-2a alone (old regimen) at a dose of 6 million units subcutaneously 3 times per week for 12 weeks. They were then tested for HCV RNA again. If they still tested positive for HCV RNA, we stopped the interferon alfa-2a treatment. Those who had become negative for HCV RNA received interferon alfa-2a at a dose of 3 million units 3 times per week for a further 36 weeks. Since October 1998, we have provided interferon alfa-2a plus ribavirin (1,000 mg or 1,200 mg per day according to body weight) for 24 or 48 weeks (new regimen). Patients with genotype 1 were given medication for 48 weeks and patients with genotype 2 or 3 for 24 weeks, in accordance with EASL recommendations. 27 All patients were assessed for adverse reaction every 4 weeks and for efficacy (HCV RNA levels) every 12 weeks during treatment. After completion of treatment, patients were evaluated at weeks 12 and 24.
Assessment of Compliance. Primary efficacy as the main criterion for good compliance for this study was defined as a loss of detectable serum HCV RNA at week 24 after treatment (sustained response). Patients who did not have a follow-up assessment for serum HCV RNA at 24 weeks were classified as nonresponders in the analysis. A few studies have shown that hepatitis C treatment with interferon alfa-2a or 2b alone was followed by a sustained response in 15% to 20%. 22, 29 Because of the postulated difficulties of the treatment of IDUs, we chose the worst result of 15% as a criterion for "good compliance." In the light of successful results of the combined treatment being between 31% (at 24 weeks) and 43% (at 48 weeks), we again took the worst result of 31% as the criterion for "good compliance." We consider the hypothesis that successful treatment of IDUs with chronic hepatitis C is possible to be confirmed if 15% and 31%, respectively, of the IDUs test negative for HCV RNA at the end of follow-up.
Statistical Analysis. Because of the small number of cases, only descriptive analyses and cross tabulations were used. The main variable, sustained response, was tested with the variables "treatment regimen," "genotype," "mean HCV RNA," "age," "sex," "setting," "employment," and "reliability in keeping appointments."
RESULTS
Between August 1997 and December 1998, 266 opiate-dependent patients were admitted to the detoxification unit. Twenty of them refused to provide a blood sample. Antibodies to HCV were discovered in 161 (65%) of the 246 remaining patients, 106 (43%) were HCV-RNA positive, and an additional human immunodeficiency virus infection was confirmed in 6 of these individuals. Fifty patients declined treatment of their hepatitis C infection. Fifty participants were enrolled in the study, 34 of whom had previously undergone inpatient detoxification. On average they were 32.5 years old (range, 19-48 years). The 50th end of follow-up was in May 2000. Average serum alanine aminotransferase was 3.1 (68.4 U/L) times higher than the upper limit of normal (22 U/L).
The 34 patients who entered the study before October 1998 were treated with interferon alfa-2a alone, whereas the 16 patients who entered after October 1998 received a combined regimen of interferon alfa-2a and ribavirin. The inpatient detoxification lasted on average 28 days. Eleven patients underwent inpatient treatment for 14 days or less, and 9 patients for more than 40 days.
Drug and Alcohol Habits of the Patients. All patients fulfilled the current ICD-10 criteria for opiate dependency. Thirty-six percent also used cocaine on a weekly basis, and 62% met the current ICD-10 criteria of benzodiazepine dependency. Forty-four percent drank alcohol daily; of these, 26% met the current ICD-10 criteria for alcohol dependency. Sixty-five percent consumed no alcohol at all; 18% consumed between 20 g and 80 g of alcohol daily, 10% consumed 100 g daily, 4% 120 g, 4% 160 g, and 2% each drank 180 g, 200 g, 220 g, or 240 g.
Compliance Hypothesis. Compliance was assessed by sustained response to therapy (loss of HCV RNA 24 weeks after the end of treatment).
After 12 weeks of treatment, 46% of patients tested negative for HCV RNA, 54% had discontinued treatment (10% because of side effects, 10% because of noncompliance, 34% because of testing positive for HCV RNA). Thirty-six percent of all patients had a sustained response ( Table 1 ). The hypothesis that IDUs with chronic HCV infection can be treated successfully with interferon alfa-2a or with a combined regimen of interferon alfa-2a and ribavirin was confirmed. Of the 50 patients 39 missed none of the interferon injections up to the end of treatment, regardless of whether "end of treatment" was because of drop out, termination of treatment due to nonresponse, or successful completion of treatment. Although 11 patients omitted between 3 and 45 of the interferon injections, 2 of them had a sustained response.
Cross Tabulation. Sustained response was similar for the variables "treatment regimen," "mean HCV RNA," and "age." In the "treatment regimen" 35% of patients were treated with interferon alfa-2a alone, compared with 38% of patients who were treated with interferon alfa-2a and ribavirin. "Mean HCV RNA" was low in 38% and high in 35%, and "age" was under 29 years in 37% (Ͻ29 years) compared with over 29 years in 35%. Forty-eight percent of patients with genotype 2 or 3, and 26% of patients with genotype 1a or 1b, had cleared HCV RNA 24 weeks after the end of treatment. Female patients had a sustained response more often than male patients (41% compared with 33%). Loss of HCV RNA was greater among employed patients compared with those who were unemployed (67% vs. 29%). After leaving inpatient detoxification treatment, 80% of patients had one or more drug relapses: 30% were admitted to a substitution maintenance program after relapse, with a sustained response in 53%. Of the 50% who were injecting drugs again (predominantly heroin), 24% showed a sustained response. Two patients implicated the severity of side effects as the cause of relapse. All other patients who relapsed once or for a sustained period attributed the relapse to their addiction. Patients who were predominantly treated in an inpatient abstinence program or were living drug free at home had a sustained response of 20% and 60%, respectively. Seventy-six percent of patients came to more than two thirds of all appointments. These patients were treated more successfully (45%) than patients who had attended less than 66.6% of the appointments (6%; P Ͻ .05; Table 2 ).
Side Effects. We decided to terminate the therapy for 5 of the 50 patients (10%) because of the magnitude of side effects. One female patient suffered hair loss, 2 patients developed severe depression, 1 patient had pancreatitis, and another experienced a weight loss of 20%. Forty-six of the patients (92%) reported a flu-like syndrome after the first injection which, after the third injection, was no longer deemed so severe. Seven patients (14%) suffered hair loss. Five patients (10%) complained of light to moderately depressive moods. In 9 patients (18%), the flu-like syndrome persisted for more than 5 days. The ribavirin treatment for 2 patients (4%) had to be interrupted when hemoglobin levels fell to less than 8 g/L.
Reinfection. HCV RNA tests were carried out 12 weeks and 24 weeks after completion of treatment. The patients with sustained response after treatment ended missed only one HCV RNA test appointment (after 12 weeks). The drug status settings were also reexamined, and the days were recorded when patients had injected heroin intravenously. None of them became reinfected, although 10 of 18 patients (56%) had relapsed and injected heroin intravenously for periods ranging from a few days to a few weeks (4-140 days; Table 3 ). Nine of the 18 patients (50%) were generally living drug free during the subsequent period of observation, although 3 of them experienced an interim relapse, taking heroin for up to 4 weeks. Six patients remained completely drug free during this period. Seven of the 18 patients (39%) were treated with methadone, and 5 of these 7 had a relapse with heroin. Two of the 18 patients (11%) had injected heroin intravenously for 20 of the 24 weeks, after a brief initial "clean" period (Table 3) .
DISCUSSION
The purpose of this study was to investigate the feasibility of HCV treatment in drug addicts. The hypothesis was that IDUs with chronic HCV infection can be treated successfully with interferon alfa-2a alone, or interferon alfa-2a and ribavirin, without insisting on a prior drug-free period of 6 to 12 months. In this prospective study, a change in the treatment regimen from interferon alfa-2a alone to interferon alfa-2a plus ribavirin was acceptable, because the aim was to investigate the compliance of the patients rather than the effectiveness of medication. For ethical reasons we changed the regimen to the current best therapy. HCV treatment with interferon alfa-2a and ribavirin is still not recommended for IDUs. 27, 28 Hepatologists postulate that IDUs have a poor compliance record. Former IDUs are usually granted treatment only if they have lived drug free for about 6 to 12 months. One reason for this long period of time could be the fact that only 54% to 73% of IDUs finish detoxification treatment successfully, 30, 31 and that 45% to 73% have a drug relapse within 6 months afterwards. 31, 32 It is well known that the illness "addiction" runs very diversely and dynamically. Phases of extreme consumption of illicit drugs alternate with drug-free phases or phases in which patients are treated in structured settings, such as methadone maintenance or inpatient or outpatient abstinence treatment programs. It is therefore easy to understand the recommendations of the hepatologists. On the other hand, hardly any data have been published about the compliance of IDUs.
The fact that 36% of IDUs had a sustained virologic response confirms the hypothesis that IDUs with chronic HCV infection can be treated successfully with interferon alfa-2a or a combination of interferon alfa-2a and ribavirin. Other studies have reported similar response rates of between 32% 24 and 38%. 25 However, some advantageous circumstances must be considered, such as the high percentage of non-genotype 1 infection and youthful age with, presumably, a relatively short duration of hepatitis C infection; these must have a beneficial effect. The prevalence of predictors for successful HCV treatment was determined for our patients: genotype 2 or 3, 24, 25, 33, 34 low virus load (Ͻ2 million copies/mL), 24, 25, 36 female gender, 24, 25 age less than 40 years, 25, 35 and absence of septal fibrosis. 24, 25, 36 Patients with genotype 2 or 3 had the highest percentage of sustained response. In the present study, the prevalence of genotype 2 or 3 was high (46% vs. 35% 25 ). Genotype 3a seems to be most common, having been found in up to 75% of IDUs. 10, 37 The sustained response of patients with genotype 2 or 3 in our study was 48%, compared with 64% in nonaddicts. 25 Despite the differences and the small number of cases in the present study, it is possible to make some interesting comparisons. The fact that patients with genotype 2 or 3 who were treated with interferon alfa alone had a similar sustained response in both our study (35%) and the European study (33%) 25 supports our hypothesis that IDUs with chronic hepatitis C virus infection can be treated successfully with interferon alfa-2a or a combination of interferon alfa-2a and ribavirin. Younger age (Ͻ40 years), female gender, and a low virus load (Ͻ2,000,000 copies/mL) were found to be additional predictors for a sustained virologic response. 25 Virus load cannot be compared with that in the two studies mentioned above 24, 25 because of the different methods of measurement. The female/male comparison was similar to other studies, 24, 25 which also showed that female patients had a sustained response more often than male patients. At the time of treatment, IDUs were younger (average 29 years) than in most other studies. On the whole, relatively young drug addicts with a high prevalence of genotype 3a constitute a group with advantageous predictors for successful HCV treatment.
After an intravenous drug relapse, 30% of patients managed to leave the drug scene, consult a physician, and obtain treatment in a maintenance methadone program. Fifty percent of patients continued injecting drugs (predominantly heroin) after relapse. In all, 80% of patients suffered a relapse. This corresponds to findings in other studies. 31, 32 Despite the high incidence of relapse, many patients had a sustained response. That patients undergoing treatment in a methadone maintenance program are able to be compliant is not surprising; 53% had a sustained response. It is also well known that methadone maintenance can stabilize addicts. [38] [39] [40] Because patients must consult a physician to receive methadone daily or at least once a week, attainment of a high level of compliance is feasible, especially if the same physicians coordinate the HCV treatment as well. Nevertheless, the sustained response in the 24% of patients who continued to inject illegal drugs, especially heroin, surprised us. Perhaps these patients developed confidence in us, even though they continued to inject illegal drugs. They wanted to maintain contact with us. We presume they would like further help from us regarding psychosocial and health aspects of their drug problems. Perhaps they feel that we are taking them seriously simply because we are treating them for a physical illness, hepatitis C. Because the weekly consultations provide an opportunity to talk about both physical and social problems, they may be the reason why so many patients injecting illegal drugs had a sustained response. A high degree of compliance can be expected of patients who were treated continuously in an inpatient abstinence program, but HCV treatment was successful only in 20% of such patients. The explanation is that the attending doctors had discontinued the HCV treatment in 2 of 5 cases, which they justified with high cost and a potential destabilization of the patients by the use of needles and syringes for interferon treatment. One of the outpatients reported that his physician refused to prescribe interferon alfa-2a because of the expense. This patient, however, did not come to us to obtain a prescription. Another patient was imprisoned and the hepatitis C treatment terminated in the prison. In contrast, the present study shows that 60% of the patients who were living drug free at home had a sustained response. In 24 weeks of follow-up, not one of the HCV-RNA-negative patients had acquired a new infection. Especially in view of the fact that 10 of the 18 patients with a sustained response had a relapse on one or more days, this was a very surprising result. We presume that these patients are a particularly motivated group of drug addicts. Of the 100 IDUs who passed the hepatitis C treatment indication, 50 decided to undergo treatment. The level of education of these 50 patients was considerably higher than that of all drug addicts as a group, 40% having passed the schoolleaving examination or graduated from high school compared with 31% of all drug addicts in the detoxification unit. 26 Also, many of the patients had steady jobs: 48% compared with 27%. 26 With regard to education and steady employment, the patients with sustained response were even better: 50% had passed the school-leaving examination or graduated from high school, and 61% had permanent employment (Table 3) . These advantageous social aspects possibly led to better comprehension of the information about infection/transmission risks and improved the patients' ability to comply. On the other hand, we suspected that the patients kept using the needles and syringes that we supplied them with during the hepatitis C treatment free of charge, continually reusing them as their own equipment. Because of these perhaps coincidentally advantageous circumstances, it is inadmissible to conclude that there is only a small risk of reinfection for drug addicts. Whether reinfection appears over a longer period (1 or 2 years) will be the subject of a further study. Severe disease and death threaten untreated patients. Furthermore, as a potential source of infection, untreated patients pose a threat to general public health. As a consequence we hope that our findings will be taken into consideration when the next HCV treatment recommendations are made.
In conclusion, the results of this prospective study indicate that IDUs with chronic hepatitis C can be treated successfully if they are living in a good social environment, including a good basic education and employment, and are treated by specialists in both addiction medicine and hepatology.
